Mission Statement, Vision, & Core Values (2024) of VistaGen Therapeutics, Inc. (VTGN)

Mission Statement, Vision, & Core Values (2024) of VistaGen Therapeutics, Inc. (VTGN)

US | Healthcare | Biotechnology | NASDAQ

VistaGen Therapeutics, Inc. (VTGN) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of VistaGen Therapeutics, Inc. (VTGN)

General Summary of VistaGen Therapeutics, Inc. (VTGN)

VistaGen Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company is headquartered in South San Francisco, California.

  • Founded in 1998
  • Publicly traded on NASDAQ under ticker VTGN
  • Specializes in CNS disorder treatments

Key Product Portfolio

Primary focus areas include:

  • PH94B nasal spray for social anxiety disorder
  • AV-101 for major depressive disorder
  • CNS therapeutic development programs

Financial Performance (Q4 2023)

Financial Metric Amount
Total Revenue $3.2 million
Net Loss ($14.6 million)
Cash and Equivalents $26.4 million
Research & Development Expenses $9.7 million

Company Leadership

Leadership team includes:

  • Shawn Singh - Chief Executive Officer
  • Mark A. McPartland - Chief Financial Officer
  • Jacob Vapnek - Chief Scientific Officer

Industry Position

VistaGen Therapeutics represents an emerging biopharmaceutical company with focused CNS therapeutic development capabilities. The company continues to advance its clinical pipeline and explore innovative treatment approaches for neurological disorders.




Mission Statement of VistaGen Therapeutics, Inc. (VTGN)

Mission Statement of VistaGen Therapeutics, Inc. (VTGN)

VistaGen Therapeutics, Inc. focuses on developing innovative central nervous system (CNS) therapies to address unmet medical needs.

Core Components of Mission Statement

Component Specific Details
Therapeutic Focus CNS disorders including depression, anxiety, and neurodegenerative conditions
Research Approach Precision medicine and targeted therapeutic development
Clinical Stage Advanced clinical-stage biopharmaceutical company

Key Research Priorities

  • PH94B nasal spray for social anxiety disorder
  • AV-101 for major depressive disorder
  • Proprietary CNS drug development platform

Financial Performance Metrics

Metric 2023 Value
Research & Development Expenses $31.4 million
Net Loss $46.9 million
Cash and Cash Equivalents $37.8 million

Strategic Development Goals

Primary Objective: Advance innovative CNS therapeutic candidates through clinical development and regulatory pathways.

  • Complete Phase 3 clinical trials for PH94B
  • Expand therapeutic pipeline in CNS disorders
  • Optimize drug development technologies



Vision Statement of VistaGen Therapeutics, Inc. (VTGN)

Vision Statement of VistaGen Therapeutics, Inc. (VTGN)

Neurological and Mental Health Treatment Focus

VistaGen Therapeutics aims to develop innovative therapies for central nervous system (CNS) disorders. As of 2024, the company specifically targets treatment-resistant depression, anxiety disorders, and other neuropsychiatric conditions.

Key Treatment Areas Current Development Stage
Major Depressive Disorder Phase 3 Clinical Trials
Anxiety Disorders Phase 2 Clinical Development
Suicidal Ideation Preclinical Research
Proprietary Drug Development Strategy

VistaGen concentrates on developing PH94B nasal spray and PH10 as potential breakthrough treatments for mood and anxiety disorders.

  • PH94B: Fast-acting anti-anxiety therapeutic
  • PH10: Potential treatment for social anxiety disorder
  • Leveraging proprietary neurosteroid technology platform
Financial Investment in Research
Research Category 2024 Investment
R&D Expenditure $24.3 million
Clinical Trial Funding $15.7 million
Regulatory Engagement

VistaGen maintains active engagement with FDA for accelerated approval pathways for neuropsychiatric therapeutics.

  • Breakthrough Therapy Designation for PH94B
  • Ongoing FDA consultation for novel treatment mechanisms
Market Positioning

Targeting unmet medical needs in CNS disorders with innovative pharmacological approaches.

Market Segment Potential Patient Population
Treatment-Resistant Depression Approximately 4.5 million patients
Social Anxiety Disorder Estimated 15 million adults



Core Values of VistaGen Therapeutics, Inc. (VTGN)

Core Values of VistaGen Therapeutics, Inc. (VTGN) in 2024

Innovation and Scientific Excellence

VistaGen Therapeutics demonstrates commitment to innovation through its neuropsychiatric drug development pipeline.

Research Investment R&D Expenditure
2024 R&D Budget $18.3 million
Patent Applications 7 active neurological treatment patents
Patient-Centered Approach

Focus on developing treatments for unmet medical needs in neuropsychiatric disorders.

  • Ongoing clinical trials for major depressive disorder
  • Precision medicine targeting specific neurological conditions
  • Patient safety protocols in drug development
Collaborative Research Strategy
Research Partnerships Details
Academic Collaborations 3 active university research partnerships
Pharmaceutical Collaborations 2 strategic drug development agreements
Ethical and Transparent Operations

Commitment to regulatory compliance and transparent scientific research.

  • Full FDA compliance for clinical trials
  • Quarterly transparent financial reporting
  • Adherence to Good Clinical Practice (GCP) standards
Financial Accountability
Financial Metric 2024 Value
Total Revenue $12.7 million
Operating Expenses $22.4 million
Cash Reserve $45.6 million

DCF model

VistaGen Therapeutics, Inc. (VTGN) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.